Metabolic syndrome and other factors associated with increased risk of diabetes (Q36039087)

11 August 2017

1 reference

title

Metabolic syndrome and other factors associated with increased risk of diabetes (English)

1 reference

11 August 2017

1 reference

Dan Streja

1

1 reference

11 August 2017

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

6 Suppl 3

1 reference

11 August 2017

S14-29

1 reference

The evolving diabetes burden in the United States

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Lifetime Risk for Diabetes Mellitus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Increased incidence of non-insulin-dependent diabetes mellitus among adolescents.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Type 2 diabetes mellitus among Florida children and adolescents, 1994 through 1998

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Are trends in diabetes incidence changing for minority children?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Economic costs of diabetes in the US in 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Diabetes and cardiovascular disease. The Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

The metabolic syndrome: diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Importance of identifying the overweight patient who will benefit the most by losing weight

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Using metabolic syndrome traits for efficient detection of impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Components of the "metabolic syndrome" and incidence of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

What is the contribution of obesity to the metabolic syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

The "metabolically-obese," normal-weight individual.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Relationships between changes in abdominal fat distribution and insulin sensitivity during a very low calorie diet in abdominally obese men and women.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Do Measures of Body Fat Distribution Provide Information on the Risk of Type 2 Diabetes in Addition to Measures of General Obesity?: Comparison of anthropometric predictors of type 2 diabetes in Pima Indians

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Evaluation of insulin release and insulin sensitivity through oral glucose tolerance test: differences between NGT, IFG, IGT, and type 2 diabetes mellitus. A cross-sectional and follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Follow-up report on the diagnosis of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Genotypic and phenotypic differences between Arabian and Scandinavian women with gestational diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Diabetes and abnormal glucose tolerance in women with previous gestational diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Prevalence and risk factors for gestational diabetes assessed by universal screening

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Insulin action in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

The association of fatty liver and diabetes risk

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Gamma-glutamyltransferase and diabetes--a 4 year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Body iron stores in relation to risk of type 2 diabetes in apparently healthy women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Influence of ethnicity and familial diabetes on glucose tolerance and insulin action: a physiological analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Elevated C-Reactive Protein Is a Risk Factor for the Development of Type 2 Diabetes in Japanese Americans

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

C-reactive protein predicts the deterioration of glycemia in chinese subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Inflammatory markers and risk of developing type 2 diabetes in women.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Adiponectin and protection against type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Adiponectin and development of type 2 diabetes in the Pima Indian population

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

The impact of weight change on cardiovascular disease risk factors in young black and white adults: the CARDIA study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

The continuing epidemics of obesity and diabetes in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Diabetes trends in the U.S.: 1990-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Weight gain as a risk factor for clinical diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Dietary patterns and risk for type 2 diabetes mellitus in U.S. men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Dietary fat intake and risk of type 2 diabetes in women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Dietary fat and incidence of type 2 diabetes in older Iowa women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Fish-seafood consumption, obesity, and risk of type 2 diabetes: an ecological study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Carbohydrates, dietary fiber, and incident type 2 diabetes in older women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Cereal, fruit, and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

A prospective study of whole-grain intake and risk of type 2 diabetes mellitus in US women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Magnesium intake and risk of type 2 diabetes in men and women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Relation between changes in intakes of dietary fiber and grain products and changes in weight and development of obesity among middle-aged women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

A prospective study of sugar intake and risk of type 2 diabetes in women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Dietary fiber, glycemic load, and risk of NIDDM in men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Dietary fiber intake and glycemic index and incidence of diabetes in African-American and white adults: the ARIC study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

A prospective study of moderate alcohol drinking and risk of diabetes in women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Alcohol consumption and risk for development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Alcohol consumption and the incidence of type 2 diabetes: a 20-year follow-up of the Finnish twin cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Alcohol drinking patterns and risk of type 2 diabetes mellitus among younger women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Physical activity and incidence of non-insulin-dependent diabetes mellitus in women.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Reproducibility and validity of a self-administered physical activity questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Walking compared with vigorous physical activity and risk of type 2 diabetes in women: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Physical activity, body mass index, and risk of type 2 diabetes in patients with normal or impaired glucose regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Moderately intense physical activities and high levels of cardiorespiratory fitness reduce the risk of non-insulin-dependent diabetes mellitus in middle-aged men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Cardiorespiratory fitness and the incidence of type 2 diabetes: prospective study of Japanese men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Physical activity and television watching in relation to risk for type 2 diabetes mellitus in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Television Watching and Other Sedentary Behaviors in Relation to Risk of Obesity and Type 2 Diabetes Mellitus in Women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Cigarette smoking and the risk of diabetes in women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

A prospective study of cigarette smoking and the incidence of diabetes mellitus among us male physicians

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Preventing type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Adverse prognostic significance of new diabetes in treated hypertensive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Diabetes Mellitus Associated with Atypical Anti-Psychotic Medications

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Physical health monitoring of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Tolerability and safety of HIV protease inhibitors in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Protease inhibitor-sparing simplified maintenance therapy: a need for perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Diabetes mellitus after kidney transplantation in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Obesity as an independent predictor of posttransplant diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Posttransplantation diabetes: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

A low incidence of new-onset insulin-dependent diabetes mellitus using tacrolimus in kidney recipients in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Islet transplantation in patients with diabetes mellitus: choice of immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes mellitus: the DA Qing IGT and Diabetes Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980094-2

7 January 2021

10.1016/S1098-3597(04)80094-2

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15707266